Compare Enveric Biosciences Inc (ENVB) vs Forgent Power Solutions Inc. Class A Common Stock (FPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Forgent Power Solutions Inc. Class A Common Stock — how do they compare? Enveric Biosciences Inc trades at $1.2 (market cap $6.27M), while Forgent Power Solutions Inc. Class A Common Stock trades at $32.19 (market cap $9.93B). The key difference: Forgent Power Solutions Inc. Class A Common Stock is far larger — about 1583.7× Enveric Biosciences Inc's market cap, and Forgent Power Solutions Inc. Class A Common Stock is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Forgent Power Solutions Inc. Class A Common Stock for 0 Days on average.
| ENVB | FPS | |
|---|---|---|
Market Cap | $6.27M | $9.93B |
Volume | 100,675 | 7,516,726 |
Sector | Health | Industrials |
52-Week High | $10.80 | $64.59 |
52-Week Low | $1.27 | $27.97 |
Typical Hold Time | 14 Days | 0 Days |
Enterprise Value | -$2.03M | $10.54B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.40, down 4.76% with a bearish technical signal from moving averages. The company shows negative profitability metrics with ROE at -235.48% and no revenue in 2025, though it has consistently beaten EPS estimates. Recent news highlights patent approvals and positive preclinical data for its neuroplastogenic therapeutics.
The outlook remains speculative given the lack of revenue and negative cash flow from operations. Analyst consensus is 75% buy, but high business execution risks and dependence on drug development success pose significant challenges for near-term shareholder value.
Forgent Power Solutions (FPS) trades at $36.17, down 2.48% on the day, following a strong earnings-driven rally. The stock shows neutral technical signals with support at $35 and resistance at $37. Recent Q2 2026 earnings beat expectations with EPS of $0.25 versus $0.24 expected, continuing a pattern of quarterly outperformance. The company reported record $3 billion backlog and strong data center demand driving growth.
FPS presents significant upside potential with analyst consensus target of $55.20 (52.9% upside) and 85.7% buy ratings. However, high valuation multiples (P/E 120.57, P/S 6.21) and negative 2025 net income of -$6.17M create valuation concerns. Key risks include execution on $3B backlog and potential overvaluation amid AI infrastructure hype.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Forgent Power Solutions Inc. Class A Common Stock
Forgent Power Solutions designs and manufactures electrical distribution equipment, including transformers, switchgear, transfer switches, and prefabricated power systems, for data centers, the power grid, and industrial facilities, manufacturing across multiple product categories in-house through a network of manufacturing campuses in US.
Read more on FPS →
